CVKD Fundamental Analysis - CADRENAL THERAPEUTICS INC

Fundamental Rating

Overall CVKD gets a fundamental rating of 2 out of 10. We evaluated CVKD against 196 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for CVKD as it has an excellent financial health rating, but there are worries on the profitability. CVKD is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

CVKD had negative earnings in the past year.

CVKD had a negative operating cash flow in the past year.

1.2 Ratios

CVKD's Return On Assets of -235.98% is on the low side compared to the rest of the industry. CVKD is outperformed by 91.33% of its industry peers.

CVKD's Return On Equity of -328.17% is on the low side compared to the rest of the industry. CVKD is outperformed by 73.98% of its industry peers.

		Industry Rank	Sector Rank
ROA	-235.98%
ROE	-328.17%
ROIC	N/A

ROA(3y)-354.52%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CVKD so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, CVKD has more shares outstanding

There is no outstanding debt for CVKD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

CVKD has an Altman-Z score of -5.08. This is a bad value and indicates that CVKD is not financially healthy and even has some risk of bankruptcy.

With a Altman-Z score value of -5.08, CVKD perfoms like the industry average, outperforming 40.82% of the companies in the same industry.

CVKD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-5.08

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 3.56 indicates that CVKD has no problem at all paying its short term obligations.

CVKD has a better Current ratio (3.56) than 61.22% of its industry peers.

CVKD has a Quick Ratio of 3.56. This indicates that CVKD is financially healthy and has no problem in meeting its short term obligations.

CVKD has a Quick ratio of 3.56. This is in the better half of the industry: CVKD outperforms 63.27% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.56
Quick Ratio	3.56

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 5.99% over the past year.

EPS 1Y (TTM)5.99%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%16.89%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

CVKD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.00% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y17.73%

EPS Next 2Y26.61%

EPS Next 3Y16.04%

EPS Next 5Y13%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

CVKD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year CVKD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as CVKD's earnings are expected to grow with 16.04% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y26.61%

EPS Next 3Y16.04%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for CVKD!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CADRENAL THERAPEUTICS INC

NASDAQ:CVKD (9/15/2025, 8:00:01 PM)

After market: 13.2 -0.17 (-1.23%)

13.365

+0.21 (+1.63%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)08-11 2025-08-11/bmo

Earnings (Next)11-05 2025-11-05

Inst Owners7.68%

Inst Owner Change-1.33%

Ins Owners4.08%

Ins Owner Change-0.74%

Market Cap27.40M

Analysts82.5

Price Target36.38 (172.2%)

Short Float %1.21%

Short Ratio0.54

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-19.88%

Min EPS beat(2)-24.94%

Max EPS beat(2)-14.82%

EPS beat(4)0

Avg EPS beat(4)-26.87%

Min EPS beat(4)-56.79%

Max EPS beat(4)-10.93%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0.21%

EPS NQ rev (3m)-11.99%

EPS NY rev (1m)-2.69%

EPS NY rev (3m)-31.95%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	6.37
P/tB	6.37
EV/EBITDA	N/A

EPS(TTM)-8.88

EYN/A

EPS(NY)-3.44

Fwd EYN/A

FCF(TTM)-5.69

FCFYN/A

OCF(TTM)-5.69

OCFYN/A

SpS0

BVpS2.1

TBVpS2.1

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-235.98%
ROE	-328.17%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-354.52%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.56
Quick Ratio	3.56
Altman-Z	-5.08

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)5.99%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%16.89%

EPS Next Y17.73%

EPS Next 2Y26.61%

EPS Next 3Y16.04%

EPS Next 5Y13%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-43.6%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-80.85%

EBIT Next 3Y-47.56%

EBIT Next 5Y-40.95%

FCF growth 1Y-108.41%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-108.41%

OCF growth 3YN/A

OCF growth 5YN/A

CADRENAL THERAPEUTICS INC (CVKD) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens